Gain Therapeutics' (GANX) Buy Rating Reiterated at BTIG Research

Key Points

• BTIG Research has reiterated a "buy" rating for Gain Therapeutics (NASDAQ: GANX) with a price target of $9.00, indicating a potential upside of 411.36% from its current price.
• Other analysts have varied projections, with Roth Capital lowering its price target from $7.00 to $6.00, while HC Wainwright maintains a buy rating with a target of $8.00, contributing to a consensus rating of "Buy."
• Gain Therapeutics reported a loss of ($0.19) earnings per share for the last quarter, missing the consensus estimate and projecting to post -1 earnings per share for the current fiscal year.

Gain Therapeutics (NASDAQ:GANX - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at BTIG Research in a research report issued on Monday,Benzinga reports. They presently have a $9.00 target price on the stock. BTIG Research's price objective would indicate a potential upside of 411.36% from the company's current price.

A number of other research analysts also recently commented on GANX. Roth Capital reduced their price objective on shares of Gain Therapeutics from $7.00 to $6.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Thursday, July 3rd. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $8.00.

Gain Therapeutics Price Performance

Shares of GANX stock opened at $1.76 on Monday. The company has a market capitalization of $63.27 million, a PE ratio of -2.79 and a beta of 0.13. The firm has a fifty day simple moving average of $1.69 and a 200-day simple moving average of $1.83. The company has a current ratio of 1.79, a quick ratio of 1.79 and a debt-to-equity ratio of 0.09. Gain Therapeutics has a twelve month low of $1.00 and a twelve month high of $3.19.

Gain Therapeutics (NASDAQ:GANX - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Equities research analysts anticipate that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GANX. Northern Trust Corp boosted its holdings in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company's stock valued at $183,000 after buying an additional 39,642 shares during the period. Bridgeway Capital Management LLC acquired a new position in shares of Gain Therapeutics in the 4th quarter valued at about $65,000. Dauntless Investment Group LLC acquired a new position in shares of Gain Therapeutics in the 1st quarter valued at about $240,000. Kovitz Investment Group Partners LLC acquired a new position in shares of Gain Therapeutics in the 1st quarter valued at about $91,000. Finally, Geode Capital Management LLC lifted its position in Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company's stock valued at $523,000 after purchasing an additional 8,251 shares during the last quarter. 11.97% of the stock is owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.